ArticleFrontiers in psychiatry2025
Trends in incidence, prevalence, and disability-adjusted life years of schizophrenia in China from 1990 to 2021, with projections for 2022-2050.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-Term Trends in the Burden of Bipolar Disorder in China, 1990-2052: An Analysis of the Global Burden of Disease Study 2023.Psychology research and behavior management · 2026Article
- Long-Term Trends in the Burden of Schizophrenia in China, 1990-2052: An Analysis of the Global Burden of Disease Study 2023.Psychology research and behavior management · 2026Article
- Global burden of schizophrenia in 204 countries and regions from 1990 to 2021 and machine learning-based projections to 2036: an analysis of the 2021 global burden of disease study.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study assessed trends in schizophrenia (SCZ) burden in China 1990-2021 and projected future trends 2022-2050. Methods: We analyzed data from the GBD 2021 study, employed the GBD method to integrate epidemiological data on age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), and age standardized disability adjusted life years rate (ASDR) to accurately assess the global burden of SCZ across various regions, genders, and age groups. Additionally, joint point regression analysis was applied to rigorously examine the time trends of anxiety disorders from 1990 to 2021, calculating the annual percentage change (APC), annual average percentage change (AAPC), and their corresponding 95% confidence intervals (CIs). Finally, a Bayesian age-period-cohort (BAPC) model was employed to predict the prevalence trends of SCZ from 2022 to 2050. Results: From 1990 to 2021, the ASPR and ASDR of SCZ in China increased steadily, with faster growth than global averages (ASPR AAPC: 0.130% vs. 0.021%; ASDR AAPC: 0.141% vs. 0.022%). In contrast, the ASIR remained stable in China (AAPC: 0.038%) but declined globally. Join point regression revealed an ASIR rebound after 2016 and an ASDR acceleration after 2016. In 2021, ASPR and ASIR peaked at ages 35-39 and 20-24, respectively, and burden growth was faster among females.The BAPC model indicates that by 2050, the ASPR of SCZ in China is projected to reach 488.3 per 100,000 population (95% UI: 216.09-760.5), while the ASDR is expected to be 315.37 per 100,000 population (95% UI: 136.88-493.87). Conclusion: GBD 2021 data reveal a rising SCZ burden in China, especially in ASPR and ASDR, posing increasing public health challenges. Males bore a consistently higher burden, but the female burden increased faster than the global average, highlighting gender-specific concerns. Age patterns emphasize young and middle-aged populations as key targets for intervention. Projected increases in incidence and mortality call for enhanced, tailored prevention and treatment strategies, improved resource allocation, and strengthened mental health services to mitigate the societal impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.